Overview of the Louisiana Therapeutic Marijuana Act - mpp.org
The Louisiana Therapeutic Marijuana Act outlines regulations for therapeutic marijuana use, impacting pharmacies involved in dispensing and monitoring controlled substances.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on August 9, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Independent pharmacies, retail chains, compounding pharmacies, and long-term-care pharmacies in Louisiana. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New regulations under the Louisiana Therapeutic Marijuana Act affecting the dispensing and monitoring of therapeutic marijuana.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, and long-term-care pharmacies in Louisiana.
What you must do
Review and comply with the new regulations regarding therapeutic marijuana dispensing and monitoring.
Deadline
Not specified.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
- PA HB 2749: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.
- Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV
- Catina Allen, N.P.; Decision and Order